National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Urethral Cancer Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 01/09/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Anterior Urethral Cancer






Posterior Urethral Cancer






Urethral Cancer Associated With Invasive Bladder Cancer






Recurrent Urethral Cancer






Get More Information From NCI






Changes to This Summary (01/09/2008)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
General Information

The prognosis of urethral cancer depends on its anatomical location and the depth of invasion. Superficial tumors located in the anterior urethra of both the female and male are generally curable; deeply invasive lesions or those lesions located in the posterior urethra, because they are almost always deeply invasive, are rarely curable by any combinations of therapy.

Female urethral cancer is more common than male urethral cancer, but both tumors are quite rare. The majority of information comes from cases accumulated over many decades at major cancer centers. Rarely, melanomas or periurethral sarcomas can occur.

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov